Genmab — Marts 2018

Bulder

Interessant: " the combination of SGN-CD48A with daratumumab produced durable complete remissions in all animals. In contrast, combination of SGN-CD48A with elotuzumab did not produce additional antitumor activity. "

E_L

it will become increasingly difficult to keep track of all; but i guess that really is a luxury-problem

bibob

Next is Dara combined with Heineken.

Bulder

Yes we'll have to wait for the studies to become clinical studies. That will make the overview easier. But really encouraging that there are so many pre-clinical opportunities.

E_L

"no hang-over the day after" - would gaurantee triple-block-buster lol

E_L

2122 / 7 - Induction of structural and functional effects of myeloma cells after daratumumab treatment http://www.abstractsonline.com/pp8/#!/4562/presentation/1807

E_L

1890 / 21 "These results suggest that treatment by inecalcitol may render 95% of AML patients sensitive to highly sensitive to anti-CD38 immunotherapy such as daratumumab." http://www.abstractsonline.com/pp8/#!/4562/presentation/6586

E_L

ok Bulder, i'll save that question for Q&A

Sukkeralf

CD47 var ellers et favorittarget for mig nogle år tilbage, men Trillium Pharmaceuticals TTI-622 har skuffet en del. Celgene roder også med CD47

Bulder

Men måske kan det hjælpe at kombinere TTI-622 med dara?: TTI-622 monotherapy demonstrated partial tumor growth inhibition. However, the therapeutic efficacy was further enhanced when TTI-622 was combined with daratumumab.

Sukkeralf

Ja det er ikke til at sige - det kan man håbe på

peter12

Lidt mere om AQR hvis man keder sig https://youtu.be/MrziV33RjNQ . Forhåbentlig skal han have revideret
sin strategi snart

E_L

Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients .....
https://clinicaltrials.gov/show/NCT03464916

Bulder

Vi skal være opmærksomme på abstract 3812 http://www.abstractsonline.com/pp8/#!/4562/presentation/8683 , der omhandler et nyt cd38 mAb fra Tusk, som også viser gode takter i solide tumorer. Desuden er der jo isatuximab, som vi tidligere har talt om. Dara får næppe monopol på PD1/PD-L1 kombi fremover. Tusk ser ud til at ville sende sin cd38 mAb i fase 1 allerede i år. https://www.tusktherapeutics.com/

Bulder

Men dara har klart fordelen af af være foran. Vi får de første resultater til sommer. De andre skal først til at starte nu.

GeorgeBest

Har Tusk en partner, eller kører de det alene?

Bulder

Ser ud til, de kører det alene indtil videre. I denne artikel mener de at deres cd38 mAb er bedre end dara h
ttps://www.tusktherapeutics.com/single-post/2017/12/21/biocentury-article-cd38-hat-trick

Bulder

https://www.tusktherapeutics.com/single-post/2017/12/21/biocentury-article-cd38-hat-trick

Solsen

Når dara sc er på markedet bliver det svært at slå ud

Bulder

Ingen tvivl om det. Sc er en stærk trumf. Færre infusionsreaktioner og måske endda mere effektivt.